Table 2.
Biological and clinical follow-up of the NMOSD patients
| Patient | Rituximab follow-up (months) | Rituximab infusions N | Mean duration between 2 infusions (months) | ARR with rituximab | CD19 count before RTX (/MM3) | Mean months for CD19+ CD27+ occurrence (min max) | Mean rituximab concentration at retreatment (µg/mL) | HACA (−, D, +) ng/mL |
|---|---|---|---|---|---|---|---|---|
| 1 AM | 26 | 4 | 7.3 (6–8) | 0 | 252 | 7.1 (6–7.9) | 0 | + |
| 2 BG | 44 | 4 | 9 (6–12.5) | 0 | 200 | 8.8 (5.8–12.2) | 0 | D |
| 3 CF | 12 | 3 | 7.1 | 0 | 79 | 7 | 0 | D |
| 4 CP | 60 | 4 | 18 (6–) | 0 | 117 | 16 (6–11.3) | 0 | – |
| 5 NY | 23 | 3 | 8.3 | 0 | 619 | 8 | 0 | + |
| 6 PN | 23 | 3 | 7.8 | 0 | 216 | 7.5 | 3.3 | D |
| 7 TMJ | 66 | 6 | 11.4 (9–16.9) | 0 | 120 | 11.1 (9–16.2) | 0 | D |
| 8 SFA | 36 | 5 | 6.9 (6–10.9) | 0 | 210 | 6.5 (6–7.1) | 0 | D |
| 9 AS | 15 | 3 | 8.1 | 0 | 318 | 8 | 0 | + |
| 10 CM | 34 | 2 | – | 0 | 151 | – | – | – |
| 11 DO | 42 | 3 | 11.6 | 0 | 838 | 11.4 | 0 | – |
| 12 VE | 36 | 3 | 13.5 | 0 | 225 | 13.2 | 0 | D |
| 13 OS | 16 | 2 | – | 0 | 234 | – | – | – |
| 14 BM | 24 | 4 | 6.4 (5.4–6.9) | 0 | 213 | 6 (5.3–6.7) | 0 | D |
| 15 SG | 20 | 3 | 6 | 0 | 274 | 6 | 0 | – |
| 16 SN | 29 | 3 | 10.8 | 0 | 301 | 10.5 | 0 | – |
| 17 GS | 24 | 3 | 7.9 | 0 | 120 | 7.5 | 0 | – |
CD19+ CD27+ memory B cells were considered positive when below 0.05%. HACA-RTX Abs: human anti-chimeric antibodies to the murine fragments of RTX: (−) Negative = 0, (D) detectable < 10 UI/mL, (+) positive > 10 UI/mL. The RTX infusion was shortly administered with the CD19+ CD27+ re-emergence